Insulin會因對於糖代謝之影響而再影響到脂肪及蛋白質的代謝，在Insulin缺乏時，自脂肪組織游離出脂肪酸的情形會亢進，血中脂蛋白(Lipoprotein)的量會增加，而顯現高血脂症(Hyperlipidemia)。Clofibrate可用來治療高血脂症及因糖尿病引起的高血壓，本計劃主要探討在常態及糖尿病狀態的ICR老鼠投與Clofibrate的降血脂效果，結果發現Clofibrate對於糖尿病狀態組有較明顯的降血脂效應，其中三甘酸油酯(Triglyceride)的下降程度較明顯，而對於膽固醇(Cholesterol)，高密度酯蛋白(High Density Lipoproteins)，極低密度酯蛋白(Very Low Density Lipoproteins)，低密度酯蛋白(Low Density Lipoproteins)，等之影響則不大。

The effects of clofibrate on various hepatic enzyme activities were studied with both healthy and diabetic young male rats. Five-week-old rats with or without diabetics were treated with clofibrate for 8 days, and plasma total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, and triglyceride werw measured. These analyses were performed in order to examine how clofibrate influence the metabolism of fat and protein. Results obtained showed that clofibrate exhibits more significant hypolipidemic effect in diabetic rats than in normal ones. In addtion, clofibrate also showed significant triglyceride lowing effect. However, plasma HDL, LDL, VLDL and total cholesterol did not differ significantly in both examined animal groups indicating the very limited effects of clofibrate on the protein or dholesterol metabolism in rats.